Vaccine makers Pfizer and BioNTech said on Friday they were "encouraged" by a new study offering early evidence that their Covid-19 vaccine might be effective against the two new coronavirus variants first identified in South Africa and the United Kingdom.
The study was conducted by researchers at Pfizer and the University of Texas Medical Branch (UTMB).
"Pfizer, BioNTech, and UTMB are encouraged by these early, in vitro study findings," according to a news release from BioNTech on Friday.
Further data are needed to monitor the Pfizer-BioNTech COVID-19 vaccine’s effectiveness in preventing COVID-19 caused by new virus variants. If the virus mutates such that an update to the vaccine is required to continue to confer protection against COVID-19, we believe that the flexibility of BioNTech’s proprietary mRNA vaccine platform is well suited to enable an adjustment to the vaccine."